Literature DB >> 1472056

A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II).

M Masuda1, H Nakashima, T Ueda, H Naba, R Ikoma, A Otaka, Y Terakawa, H Tamamura, T Ibuka, T Murakami.   

Abstract

Tachyplesin and polyphemusin are antimicrobial peptides recently isolated from the hemocytes of horseshoe crabs (Tachypleus tridentatus and Limulus polyphemus). We synthesized them and their analogs and examined their antiviral activity against human immunodeficiency virus (HIV) type 1 in vitro. The infection of human T cells with the virus was markedly inhibited by some of them at low concentrations. In this structure-activity study, we found that [Tyr5,12, Lys7]-polyphemusin II, which was designated as T22, had extremely high anti-HIV activity. Its 50% inhibitory concentration (EC50) was 0.008 micrograms/ml, while its 50% cytotoxic concentration (CC50) was 54 micrograms/ml and these values were comparable to those of AZT. This result indicates that T22 would be a potential candidate for the therapy of HIV infection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1472056     DOI: 10.1016/0006-291x(92)92280-b

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  24 in total

1.  A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity.

Authors:  Kozi Ichiyama; Sei Yokoyama-Kumakura; Yuetsu Tanaka; Reiko Tanaka; Kunitaka Hirose; Kenji Bannai; Takeo Edamatsu; Mikiro Yanaka; Yoshiaki Niitani; Naoko Miyano-Kurosaki; Hiroshi Takaku; Yoshio Koyanagi; Naoki Yamamoto
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-17       Impact factor: 11.205

Review 2.  Peptide antimicrobial agents.

Authors:  Håvard Jenssen; Pamela Hamill; Robert E W Hancock
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

Review 3.  Studies on anticancer activities of antimicrobial peptides.

Authors:  David W Hoskin; Ayyalusamy Ramamoorthy
Journal:  Biochim Biophys Acta       Date:  2007-11-22

Review 4.  Multimodality imaging of CXCR4 in cancer: current status towards clinical translation.

Authors:  T R Nayak; H Hong; Y Zhang; W Cai
Journal:  Curr Mol Med       Date:  2013-12       Impact factor: 2.222

Review 5.  Discoveries and developments of CXCR4-targeted HIV-1 entry inhibitors.

Authors:  Chaozai Zhang; Ruohan Zhu; Qizhi Cao; Xiaohong Yang; Ziwei Huang; Jing An
Journal:  Exp Biol Med (Maywood)       Date:  2020-02-04

6.  Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection.

Authors:  T Murakami; T Y Zhang; Y Koyanagi; Y Tanaka; J Kim; Y Suzuki; S Minoguchi; H Tamamura; M Waki; A Matsumoto; N Fujii; H Shida; J A Hoxie; S C Peiper; N Yamamoto
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

7.  Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target.

Authors:  Federica Barbieri; Adriana Bajetto; Tullio Florio
Journal:  J Oncol       Date:  2009-12-14       Impact factor: 4.375

8.  Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor.

Authors:  P F Lin; H Samanta; C M Bechtold; C A Deminie; A K Patick; M Alam; K Riccardi; R E Rose; R J White; R J Colonno
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

9.  Fragment-based optimization of small molecule CXCL12 inhibitors for antagonizing the CXCL12/CXCR4 interaction.

Authors:  Joshua J Ziarek; Yan Liu; Emmanuel Smith; Guolin Zhang; Francis C Peterson; Jun Chen; Yongping Yu; Yu Chen; Brian F Volkman; Rongshi Li
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

10.  Exploratory studies on development of the chemokine receptor CXCR4 antagonists toward downsizing.

Authors:  Hirokazu Tamamura; Hiroshi Tsutsumi; Wataru Nomura; Nobutaka Fujii
Journal:  Perspect Medicin Chem       Date:  2008-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.